Amendments to the specification:

Following the section entitled "Abstract of the Disclosure" and before the Figures, please insert the paper copy of the "Sequence Listing", attached hereto as **Exhibit B.**

In addition, please amend the specification as follows:

On page 13, lines 1-14, please delete the paragraph which begins on line 1 and insert the following paragraph:

added and the complete reaction mixture was incubated for 45 min at 30°C in a final volume of 25 μl. The reaction was terminated by adding 175 μl of stop mix (0.1 M sodium acetate (pH 5.2), 10 mM EDTA, 0.1% SDS, 200 μl/ml tRNA) followed by phenol extraction and ethanol precipitation. RNA was resuspended in sample buffer containing 80% formamide and 10 mM Tris-HCL (pH 7.4) and separated on 5% polyacrylamide gel containing 7 M urea in TBE. Correctly initiated transcripts were quantitated by PhosphorImager analysis. The test DNA template was constructed by inserting into pC_2AT19 plasmid a PCR-amplified oligonucleotide prepared by using the $(C3P)_3$-TK-CAT plasmid as template and consisting of three copies of the C3P element of the Apo CIII promoter sequence (-87/-66) having an EcoRI and SSTI sites at the 5' and 3' ends, respectively. The resultant plasmid was cleaved with sphI and sacI and ligated to a synthetic oligonucleotide (5'-CGAGGTCCACTTCGCTATATATTCCCCGAGCT-3') (SEQ ID NO:1) containing sequences of the HSV thymidine kinase promoter

(-41/-29) and of the chicken ovalbumin promoter (-33/-21).

On page 13, lines 17-27, please delete the paragraph which begins on line 17 and insert the following paragraph:

COS-7 cells cotransfected for 6h with the $(C3P)_3$-TK-CAT reporter plasmid (5 μg) and with either pSG5-HNF-4α expression plasmid (0.025 μg) or the pSG5 plasmid (0.025 μg) added by calcium phosphate precipitation were cultured in serum free medium with fatty acids (complexed with albumin in a molar ration of 6:1) added as indicated. B-Galactosidase expression vector pRSGAL (1 μg) added to each precipitate served as an internal control for transfection. The $(C3P)_3$-TK-CAT construct by prepared by inserting a synthetic oligonucleotide encompassing the (-87/-66) Apo CIII promoter sequence (5'-GCAGGTGACCTTTGCCCAGCGCC-3') (SEQ ID NO:2) flanked by HindIII restriction site into pBLCAT2[47] upstream of the -105 bp thymidine kinase promoter. The construct containing three copies of the synthetic oligonucleotide in the direct orientation was selected and confirmed by sequencing.